New data suggest InterMune Inc.'s intravenous oritavancin is as effective as a regimen of vancomycin plus cephalexin in treating patients with complicated skin and skin-structure infections (CSSSI).
Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
5 Perspectives on Laser Treatment in Dermatology
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Adel Haque, MD, Provides His Best Advice for New Dermatologists
Recent Povorcitinib 2b Study Shows Improved Repigmentation